Patents Assigned to Veridex, LLC
-
Patent number: 8940493Abstract: Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.Type: GrantFiled: May 29, 2007Date of Patent: January 27, 2015Assignees: Veridex LLC, Pfizer Inc.Inventors: Antonio Gualberto, Maria Luisa Paccagnella, Carrie L. Melvin, Madeline I. Repollet, David Chianese, Mark Carle Connelly, Leonardus Wendelinus Mathias Marie Terstappen
-
Publication number: 20140315192Abstract: Methods and kits for predicting the course or aggressiveness of prostate cancer include detecting the methylation status of various genes.Type: ApplicationFiled: March 6, 2013Publication date: October 23, 2014Applicant: Veridex, LLCInventors: HAIYING WANG, SHOBHA VARDE, DONDAPATI CHOWDARY, JYOTI MEHROTRA, TATIANA VENER, ABHIJIT MAZUMDER
-
Publication number: 20140295426Abstract: A method for diagnosing or differentially diagnosing a cancer characterized by the presence of cancer cells in the pleural fluid of a mammalian subject, the method comprising contacting a sample of pleural fluid of the subject with colloidal magnetic particles coupled to a ligand which binds to a determinant on a cancer cell, but does not bind above a baseline threshold to other cellular and non-cellular components in pleural fluid; subjecting the pleural fluid-magnetic particle mixture to a magnetic field to produce a cell fraction enriched in ligand coupled-magnetic particle-bound cancer cells, if present in the pleural fluid; and analyzing the enriched fraction for the number of cancer cells in the pleural fluid. In certain aspects, this method involves preparing the pleural fluids for the above-noted method steps by, e.g., dilution of unprocessed pleural fluid. In certain aspect, the pleural fluid is subjected to the diagnostic method within 24 hours of withdrawal from the subject.Type: ApplicationFiled: July 27, 2012Publication date: October 2, 2014Applicants: VERIDEX LLC, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Steven M. Albelda, Daniel Schwed, Chandra Galla Rao, Mark Connelly, Brad Foulk
-
Publication number: 20140038230Abstract: The enumeration of cells in fluids by flow cytometry is widely used across many disciplines such as assessment of leukocyte subsets in different bodily fluids or of bacterial contamination in environmental samples, food products and bodily fluids. For many applications the cost, size and complexity of the instruments prevents wider use, for example, CD4 analysis in HIV monitoring in resource-poor countries. The novel device, methods and system disclosed herein largely overcome these limitations. The system includes a simple system for CD4 and CD8 counting in point-of-care HIV staging within resource poor countries. Unlike previous approaches, no sample preparation is required with the sample added directly to a chip containing dried reagents by capillary flow.Type: ApplicationFiled: May 8, 2011Publication date: February 6, 2014Applicant: Veridex, LLCInventors: Markus Beck, Leon L.W.M.M. Terstappen
-
Patent number: 8569077Abstract: A method for removing excess unbound ferrofluid and imaging immunomagnetically enriched circulating tumor cells is provided. A vessels having a preformed grooves in the viewing surface is optimally designed for cell alignment and imaging. After separating the unbound particles by centrifugation, an externally-applied force is applied to transport magnetically responsive particle-CTC complex toward the transparent collection wall. The grooved inner surface of the viewing face of the chamber provide uniform distribution of the particles for easy imaging. The invention is also useful in conducting quantitative analysis and sample preparation in conjunction with automated cell enumeration techniques as in quantitative analysis of CTC in disease.Type: GrantFiled: May 18, 2009Date of Patent: October 29, 2013Assignee: Veridex, LLCInventors: Tyco M. Scholtens, Frederik Schreuder, Jan Greve, Arjan G. J. Tibbe, Leon W. M. M. Terstappen
-
Publication number: 20130217011Abstract: Methods are disclosed for the identification of gene sets that are differentially expressed in PBMCs of patients diagnosed with a pre-diabetic disease state and overt type II diabetes. 3 gene and 10 gene signatures are shown to accurately predict a diabetic disease state in a patient. The application also described kits for the rapid diagnosis of diabetic disease states in patients at a point of care facility.Type: ApplicationFiled: December 4, 2012Publication date: August 22, 2013Applicant: Veridex, LLCInventor: Veridex, LLC
-
Publication number: 20130157347Abstract: Compositions, systems, and methods comprising circulating endothelial cells (CECs) are provided. The compositions described herein utilize isolated CECs, including compositions in a form that allows analysis of the CECs. The systems described herein utilize isolated CECs and an analytical tool or an output from an analytical tool. The methods described herein are related to the use of isolated CECs and analytical tools for providing information, to a health care provider or the CEC donor, that is relevant to the cardiovascular health of the CEC donor. Thus, the compositions, systems and methods described herein involve both a transformation (e.g., non-isolated CECs to isolated CECs, or isolated CECs to analyzed CECs) and a machine (e.g., isolation tools and analytical tools).Type: ApplicationFiled: July 6, 2012Publication date: June 20, 2013Applicants: Veridex, LLC, Scripps HealthInventors: Eric Topol, Samir Damani, Mark Connelly, Galla Chandra Rao
-
Publication number: 20130130999Abstract: The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide.Type: ApplicationFiled: January 25, 2013Publication date: May 23, 2013Applicant: Veridex, LLCInventor: Veridex, LLC
-
Patent number: 8337755Abstract: The present invention provides a protocol and apparatus for enriching circulating tumor cells and other rare cells from blood, including debris and other components, from samples with high precision and at high throughput rates. This invention discloses an improved processing system from previously described semi-automated sample processing. The system further reduces operator intervention and hands-on time from prior systems. While this system has general utility in processing diverse materials, the system is configured for sample processing of biological specimens to provide an enriched fraction suitable for detection, enumeration and identification of target cells by appropriate analytical methodologies.Type: GrantFiled: March 13, 2006Date of Patent: December 25, 2012Assignee: Veridex, LLCInventors: Teresa Bendele, Thomas Harbart, Dave Howard, Michael Kagan, Douglas Keene, Dave Lapeus, Jared Mayes, Douglas Paynter, Jerry Prohaska, Herman Rutner
-
Patent number: 8329422Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CELLSPOTTER® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.Type: GrantFiled: November 2, 2010Date of Patent: December 11, 2012Assignee: Veridex LLCInventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W. M. M. Terstappen, Shawn Mark O'Hara, Steven Gross
-
Patent number: 8189899Abstract: The enumeration of cells in fluids by flow cytometry is widely used across many disciplines such as assessment of leukocyte subsets in different bodily fluids or of bacterial contamination in environmental samples, food products and bodily fluids. For many applications the cost, size and complexity of the instruments prevents wider use, for example, CD4 analysis in HIV monitoring in resource-poor countries. The novel device, methods and algorithms disclosed herein largely overcome these limitations. Briefly, all cells in a biological sample are fluorescently labeled, but only the target cells are also magnetically labeled. In addition, non-magnetically labeled cells are imaged for viability in a modified slide configuration. The labeled sample, in a chamber or cuvet, is placed between two wedge-shaped magnets to selectively move the magnetically labeled cells to the observation surface of the cuvet.Type: GrantFiled: February 17, 2010Date of Patent: May 29, 2012Assignee: Veridex, LLCInventors: Frank A. W. Coumans, Jan Greve, Frank P. Modica, Leon W. M. M. Terstappen, Arjan G. J. Tibbe, John A. Verrant
-
Patent number: 8183353Abstract: A method of providing a prognosis of breast cancer is conducted by analyzing the expression of a group of genes. Gene expression profiles in a variety of medium such as microarrays are included as are kits that contain them.Type: GrantFiled: October 25, 2007Date of Patent: May 22, 2012Assignee: Veridex, LLC.Inventor: Yixin Wang
-
Patent number: 8128890Abstract: The enumeration of cells in fluids by flow cytometry is widely used across many disciplines such as assessment of leukocyte subsets in different bodily fluids or of bacterial contamination in environmental samples, food products and bodily fluids. For many applications the cost, size and complexity of the instruments prevents wider use, for example, CD4 analysis in HIV monitoring in resource-poor countries. The novel device, methods and algorithms disclosed herein largely overcome these limitations. Briefly, all cells in a biological sample are fluorescently labeled, but only the target cells are also magnetically labeled. The labeled sample, in a chamber or cuvet, is placed between two wedge-shaped magnets to selectively move the magnetically labeled cells to the observation surface of the cuvet. An LED illuminates the cells and a CCD camera captures the images of the fluorescent light emitted by the target cells.Type: GrantFiled: November 1, 2010Date of Patent: March 6, 2012Assignee: Veridex, LLCInventors: Erik Droog, Dhanesh Gohel, Arjan G. J. Tibbe, Jan Greve, Leon W. M. M. Terstappen
-
Patent number: 8110101Abstract: A system for enumeration of cells in fluids by image cytometry is described for assessment of target populations such as leukocyte subsets in different bodily fluids or bacterial contamination in environmental samples, food products and bodily fluids. Briefly, all cells in a biological sample are fluorescently labeled, but only the target cells are also magnetically labeled. A small, permanent magnet is inserted directly into the chamber containing the labeled sample. The magnets are coated with PDMS silicone rubber to provide a smooth and even surface which allows imaging on a single focal plane. The cells are illuminated and the images of the fluorescent light emitted by the target cells are captured by a CCD camera. Image analysis performed with a novel algorithm provides a count of the cells on the surface that can be related to the target cell concentration of the original sample.Type: GrantFiled: August 30, 2007Date of Patent: February 7, 2012Assignee: Veridex, LLCInventors: Arjan G. J. Tibbe, Leon W. M. M. Terstappen
-
Patent number: 7943397Abstract: The enumeration of cells in fluids by flow cytometry is widely used across many disciplines such as assessment of leukocyte subsets in different bodily fluids or of bacterial contamination in environmental samples, food products and bodily fluids. For many applications the cost, size and complexity of the instruments prevents wider use, for example, CD4 analysis in HIV monitoring in resource-poor countries. The novel device, methods and algorithms disclosed herein largely overcome these limitations. Briefly, all cells in a biological sample are fluorescently labeled, but only the target cells are also magnetically labeled. The labeled sample, in a chamber or cuvet, is placed between two wedge-shaped magnets to selectively move the magnetically labeled cells to the observation surface of the cuvet. An LED illuminates the cells and a CCD camera captures the images of the fluorescent light emitted by the target cells.Type: GrantFiled: July 30, 2004Date of Patent: May 17, 2011Assignee: Veridex, LLCInventors: Arjan Tibbe, Jan Greve, Dhanesh Gohel, Erik Droog, Leon W. M. M. Terstappen
-
Publication number: 20110104718Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.Type: ApplicationFiled: November 2, 2010Publication date: May 5, 2011Applicant: VERIDEX, LLCInventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W.M.M. Terstappen, Shawn Mark O'Hara, Steven Gross
-
Patent number: 7932036Abstract: We analyzed bone marrow from 67 patients from a phase 2 study of farnesyltransferase inhibition with tipifarnib (R115777, ZARNESTRA®), in older adults with previously untreated, poor-risk acute myeloid leukemia (AML) for N-Ras mutations, global gene expression, and/or quantitative PCR (qPCR) of specific genes. Microarray profiling identified a two-gene expression ratio (RASGRP1:APTX) which provided the greatest accuracy for predicting response to tipifarnib. We demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a NPV and PPV of 92% and 28%, respectively (odds ratio of 4.4). Therefore, in both newly diagnosed and relapsed or refractory AML, this classifier improves the overall response rate by approximately 50% while maintaining a high NPV, and significantly improves patient overall survival.Type: GrantFiled: March 12, 2008Date of Patent: April 26, 2011Assignee: Veridex, LLCInventors: Mitch Raponi, Yixin Wang, Hongtao Fan
-
Patent number: 7927805Abstract: Disclosed in this specification is a method for predicting the prognosis of squamous cell lung cancer by observing regulatory changes in select miRNA sequences. These sequences may include hsa-mir-146b, hsa-mir-191, hsa-mir-206, hsa-mir-299-3p, hsa-mir-155, hsa-mir-15a, hsa-mir-122a, hsa-mir-513, hsa-mir-184, hsa-mir-511, hsa-mir-100, hsa-mir-10a, hsa-mir-453, hsa-mir-379, hsa-mir-202, hsa-mir-21, hsa-mir-126, hsa-mir-494, hsa-mir-432, hsa-mir-370, and combinations of these sequences.Type: GrantFiled: October 30, 2008Date of Patent: April 19, 2011Assignee: Veridex, LLCInventors: Mitch Raponi, Lesley Estelle Dossey
-
Patent number: 7901950Abstract: Elevated number of Circulating Endothelial Cells (CEC) have been implicated in disease conditions associated with the formation or destruction of blood vessels such as acute coronary syndrome, thrombocytopenic purpura, sickle cell disease, sepsis, lupus, nephrotic syndromes, rejection of organ transplants, surgical trauma and cancer. This invention provides a method for assessing the levels of CEC which vary between different studies using a sensitive enrichment, imaging, and enumberation analysis. CD146 is one of the most specific endothelium-associated cell-surface antigens which can be used in image cytometry. CEC analysis provides an essential tool in prognostic/diagnostic evaluation in the clinic.Type: GrantFiled: February 2, 2007Date of Patent: March 8, 2011Assignee: Veridex, LLCInventors: Mark Carle Connelly, Gerald V. Doyle, Galla Chandra Rao, Leon W. M. M. Terstappen
-
Publication number: 20110052037Abstract: The enumeration of cells in fluids by flow cytometry is widely used across many disciplines such as assessment of leukocyte subsets in different bodily fluids or of bacterial contamination in environmental samples, food products and bodily fluids. For many applications the cost, size and complexity of the instruments prevents wider use, for example, CD4 analysis in HIV monitoring in resource-poor countries. The novel device, methods and algorithms disclosed herein largely overcome these limitations. Briefly, all cells in a biological sample are fluorescently labeled, but only the target cells are also magnetically labeled. In addition, non-magnetically labeled cells are imaged for viability in a modified slide configuration. The labeled sample, in a chamber or cuvet, is placed between two wedge-shaped magnets to selectively move the magnetically labeled cells to the observation surface of the cuvet.Type: ApplicationFiled: February 17, 2010Publication date: March 3, 2011Applicant: VERIDEX, LLCInventors: Frank A.W. Coumans, Jan Greve, Frank P. Modica, Leon W.M.M. Terstappen, Arjan G.J. Tibbe, John A. Verrant